قالب وردپرس درنا توس
Home / Health / OHSU seeks AstraZeneca Coronavirus Phase 3 clinical trial for residents of Portland area

OHSU seeks AstraZeneca Coronavirus Phase 3 clinical trial for residents of Portland area



Officials said Monday that researchers at Oregon Health and Science University are looking for residents of the Portland area to participate in the Phase III trial of the experimental coronavirus vaccine.

The university is the only institution in Oregon to participate in the trial of this special vaccine developed by Oxford University and AstraZeneca Pharmaceuticals. The trial is looking for as many as 30,000 volunteers across the country.

Dr. Danny Jacobs, President of OHSU, said in a statement: “Oregon Health and Science University is proud to contribute to the most pressing challenges in the world today: a safety for all. An effective COVID-1

9 vaccine.” “We are asking residents of the Portland area to voluntarily participate in this trial and help all of us further stop this devastating pandemic.”

To participate, volunteers must have stable medical conditions or no medical problems, and cannot be pregnant or have a previous diagnosis of COVID-19. Participants must live within a 90-minute drive of the OHSU campus in Southwest Portland. Officials said those who participated in the event will be monitored for two years.

Officials said the university hopes to recruit a variety of participants, and the lead researcher of the project, Dr. Marcel Curlin has been holding virtual meetings with community groups to explain the process and encourage people to participate.

Throughout the summer, OHSU was forced to cancel an unrelated coronavirus study that hoped to recruit 100,000 Oregonians after minority ethnic groups signed up.

According to a research paper published in The Lancet, the earlier AstraZeneca vaccine trial in the United Kingdom showed a “robust” immune response and only had mild to moderate side effects, including headache, fatigue and Chills. According to ABC News, last week, the company was criticized for how it provided data from some European trials. Some previous results seemed to indicate that subjects taking lower doses had higher efficacy. A company spokesperson defended the trial and told ABC News that “their behavior met the highest standards.”

The experimental vaccine from AstraZeneca is one of three vaccines currently in late-stage trials. On Monday, Moderna Inc., which is developing one of the other vaccine candidates, plans to require U.S. and European regulatory agencies to allow emergency use of its treatment methods, starting vaccination as soon as next month.

Officials asked those interested in participating in the Portland area trial to visit the vaccine research website or call 888-VAC-STDY for more information.

-Kale Williams kwilliams@oregonian.com; 503-294-4048; @sfkale


Source link